Perampanel in lissencephaly-associated epilepsy
| Autor: | Shin-ichiro Hamano, Yuko Hirata, Reiko Koichihara, Satoru Ikemoto, Ryuki Matsuura |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Pediatrics medicine.medical_specialty Lissencephaly Neuronal migration disorder Perampanel Article lcsh:RC321-571 03 medical and health sciences Behavioral Neuroscience chemistry.chemical_compound Epilepsy 0302 clinical medicine DRPLA dentatorubral–pallidoluysian atrophy medicine GTCS generalized tonic–clonic seizures Adverse effect lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry AMPA alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid Seizure frequency business.industry NMDA N-methyl-d-aspartate medicine.disease 030104 developmental biology Neurology chemistry Concomitant Etiology PER perampanel Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | Epilepsy and Behavior Case Reports, Vol 11, Iss, Pp 67-69 (2019) Epilepsy & Behavior Case Reports |
| ISSN: | 2213-3232 |
| DOI: | 10.1016/j.ebcr.2019.01.001 |
| Popis: | We retrospectively investigated whether perampanel (PER) could serve as an alternative for treating drug-resistant seizures in lissencephaly. We investigated the following data: age at onset of epilepsy, age at start of PER, etiology, brain MRI findings, seizure type, seizure frequency, adverse effects, and concomitant anti-epileptic drugs. There were 5 patients with lissencephaly, including 2 with Miller–Dieker syndrome. Four out of five patients exhibited ≥ 50% seizure reduction. Myoclonic seizures disappeared in 1 patient. PER was an effective adjunctive anti-seizure drug in our series of patients with lissencephaly. Highlights • PER could treat drug-resistant seizures of patients with lissencephaly. • PER could be effective against epileptic myoclonus in lissencephaly. • AMPA receptor phenotype in neuronal migration disorder may explain effects of PER. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|